Patents Represented by Attorney, Agent or Law Firm Kathleen M. Williams
-
Patent number: 6498020Abstract: The present invention relates to a fusion protein comprising a first amino acid sequence comprising the sequence of the C-terminal 40 amino acids of bovine IF1 ATPase inhibitor protein, and a second amino acid sequence not naturally associated with the first region. The invention further relates to methods for preparing an immunoglobulin comprising immunizing an animal with the fusion protein and recovering immunoglobulin specific for a region of the fusion protein.Type: GrantFiled: December 27, 1999Date of Patent: December 24, 2002Assignee: Medical Research CouncilInventors: John Walker, Bruno Miroux
-
Patent number: 6495351Abstract: A loading system for providing a cell suitable for delivery of an agent to a vertebrate, the system comprise a loading module for loading a cell with an agent; and a sensitisation module in fluid communication with the loading module, the sensitisation module for sensitising a cell to an energy field, such that said cell is induced to release the agent upon exposure to said energy field. The system can be used to transform a cell, such as a red blood cell, into a delivery vehicle for delivering a therapeutic agent and/or an imaging agent to a vertebrate, and in particular, to a mammal, such as a human being.Type: GrantFiled: February 8, 2001Date of Patent: December 17, 2002Assignee: Gendel LimitedInventor: Anthony Patrick McHale
-
Patent number: 6485960Abstract: The present invention relates to the polycystic kidney disease 1 (PKD1) gene and its nucleic acid sequence, mutations thereof in patients having PKD1-associated disorders, the protein encoded by the PKD1 gene or its mutants, and their uses in disease diagnosis and therapy.Type: GrantFiled: April 14, 1995Date of Patent: November 26, 2002Assignee: Medical Research CouncilInventors: Peter Charles Harris, Belen Peral, Christopher J. Ward, James Hughes, Martin Hendrik Breuning, Dorothea Johanna Maria Peters, Jeroen Hendrik Roelfsema, Julian Sampson, Dirkje Jorijntje Johanna Halley, Mark David Nellist, Lambertus Antonius Jacobus Janssen, Ajenne Lique Wilhelma Hesseling
-
Patent number: 6465199Abstract: This invention relates to methods and compositions for monitoring enzymatic activity as a function of the the interaction of binding partners, wherein binding is dependent upon addition or subtraction of a chemical moiety to or from one of the binding partners by a protein modifying enzyme.Type: GrantFiled: February 26, 1999Date of Patent: October 15, 2002Assignee: Cyclacel, Ltd.Inventors: Roger K. Craig, John Colyer
-
Patent number: 6392121Abstract: A gene amplification system based on plant viral genetic elements dramatically increases foreign protein production in plants. A safer and more economical production system for vaccines and antibodies in recombinant plants grown using agricultural practice is described. The high-level expression system uses the replicative process of a plant mastrevirus, exemplified by bean yellow dwarf virus (BeYDV). The expression system is preferably inducible to avoid interference with plant growth and development. Developmental cues, such as fruit ripening, are employed to trigger expression of the foreign protein using a tissue-specific promoter. A single, stably integrated expression cassette for foreign protein is replicated extrachromosomally in ripening fruit, forming hundreds of transcriptionally competent copies. Preferred plant hosts include tomato as a model system and soybean for production of large quantities of protein at high total protein levels.Type: GrantFiled: October 7, 1999Date of Patent: May 21, 2002Assignee: Boyce Thompson Institute for Plant ResearchInventors: Hugh S. Mason, Kenneth E. Palmer, Kathleen L. Hefferon, Tsafrir S. Mor, Charles Arntzen
-
Patent number: 6387686Abstract: Methods are disclosed whereby protease activity is directly linked to delivery of a transferable label to a target cell which expresses a protease, via fusion of viral display packages comprising the transferable label with the target cell. The methods can be used, inter alia, to identify proteases, including previously undiscovered proteases or variants of known proteases which may have altered substrate specificity.Type: GrantFiled: February 23, 2001Date of Patent: May 14, 2002Assignee: BioFocus Discovery LimitedInventors: Mark P. Chadwick, Stephen J. Russell, Christian Buchholz
-
Patent number: 6380360Abstract: The present invention relates to the polycystic kidney disease 1 (PKD1) gene and its nucleic acid sequence, mutations thereof in patients having PKD1-associated disorders, the protein encoded by the PKD1 gene or its mutants, and their uses in disease diagnosis and therapy.Type: GrantFiled: March 31, 1998Date of Patent: April 30, 2002Assignee: Medical Research CouncilInventors: Peter Charles Harris, Belen Peral, Christopher J. Ward, James Hughes, Martin Hendrik Breuning, Dorothea Johanna Maria Peters, Jeroen Hendrik Roelfsema, Julian Sampson, Dirkje Jorijntje Johanna Halley, Mark David Nellist, Lambertus Antonius Jacobus Janssen, Ajenne Lique Wilhelma Hesseling
-
Patent number: 6350580Abstract: The invention relates to a method of generating a signal indicative of the presence of a target nucleic acid sequence in a sample, where the method includes forming a cleavage structure by incubating a sample comprising a target nucleic acid sequence with a probe having a secondary structure that changes upon binding of the probe to the target nucleic acid sequence, and cleaving the cleavage structure with a nuclease to release a nucleic acid fragment to generate a signal, wherein generation of the signal is indicative of the presence of a target nucleic acid sequence in a sample.Type: GrantFiled: October 11, 2000Date of Patent: February 26, 2002Assignee: StratageneInventor: Joseph A. Sorge
-
Patent number: 6322976Abstract: The invention pertains to isolated nucleic acid molecules containing sequences specified herein, to mutant CD36 genes and their encoded gene products, to methods of screening blood or a blood product by detecting a CD36 gene mutation, methods of administering blood or a blood product based on the presence or absence of a CD36 gene mutation, to methods of matching a biological sample donor with a recipient based on detection of a mutation in the CD36 gene, methods of determining the resistance of a patient to infection by a parasite by detecting a CD36 gene mutation, methods of diagnosing a disease associated with a defect in insulin action, glucose metabolism, fatty acid metabolism, and/or catecholamine action by detecting a mutation in the CD36 gene, and methods of disease treatment by altering the mutation(s).Type: GrantFiled: March 17, 1999Date of Patent: November 27, 2001Assignees: Medical Research Council, SCIOS, Inc.Inventors: Timothy J. Aitman, James Scott, Lawrence W. Stanton
-
Patent number: 6297004Abstract: We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.Type: GrantFiled: February 27, 1998Date of Patent: October 2, 2001Assignee: Cambridge Drug Discovery Holding, LTDInventors: Stephen J. Russell, Robert E. Hawkins, Gregory P. Winter
-
Patent number: 6274310Abstract: Methods for screening a patient for pancreatic disease are disclosed and are based upon detection of a mutation in the gene encoding insulin promoter factor-1 (IPF-1) which is linked to diabetes mellitus and pancreatic agenesis.Type: GrantFiled: June 24, 1997Date of Patent: August 14, 2001Assignee: The General Hospital CorporationInventors: Joel F. Habener, Doris A. Stoffers
-
Patent number: 6270761Abstract: Disclosed are various compositions for use in the delivery of nucleic acid to a target cell including: a composition comprising a calcium salt in particulate form, the nucleic acid to be delivered, and one or more further components to enhance the efficiency of delivery of the nucleic acid to a target cell, the nucleic acid and the one or more further components being complexed with the particulate calcium salt; and methods of delivering a nucleic acid to a target cell.Type: GrantFiled: June 29, 1998Date of Patent: August 7, 2001Assignee: Cambridge Drug Discovery Holdings, LTDInventors: Stephen James Russell, Frances Joanne Morling
-
Patent number: 6264948Abstract: A method of suppressing tumor cell growth, comprising administering to a mammal in need thereof an amount of an inhibitor of eosinophilia sufficient to result in suppression of tumor cell growth is disclosed.Type: GrantFiled: December 8, 1998Date of Patent: July 24, 2001Assignee: Beth Israel Deaconess Hospital, Inc.Inventors: David T. W. Wong, Peter F. Weller
-
Patent number: 6224870Abstract: The invention provides compositions and methods for modulating immune responses in subjects. The invention is based, at least in part, on the discovery that an in-frame translation fusion of an antigen with an APC binding domain of an opsonin forms a molecule, that is, a fusion polypeptide, which when administered to a subject modulates an immune response to the antigen.Type: GrantFiled: January 15, 1998Date of Patent: May 1, 2001Assignee: Genitrix, Ltd.Inventor: Andrew H. Segal
-
Patent number: 6217846Abstract: Radioactively labeled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumor or CAM markers for the in vivo diagnosis and detection of thrombi, tumors or CAM in mammals.Type: GrantFiled: January 21, 1998Date of Patent: April 17, 2001Assignee: Antisoma Research LimitedInventor: Alan William John Stuttle
-
Patent number: 6207374Abstract: Tuberous sclerosis (TSC) is an autosomal dominant disorder characterised by widespread development of growths in many tissues and organs. A gene (TSC2) is identified on chromosome 16 which is mutated in TSC and which may behave as a tumour suppressor. Screening of actual or suspected TSC patients for normal or mutated TSC2 can be used for diagnostic purposes. TSC2 protein (tuberin) may be used to treat or prevent unrestrained cell division and/or tumour development in patients with or without TSC.Type: GrantFiled: March 18, 1998Date of Patent: March 27, 2001Assignee: Medical Research CouncilInventors: Julian R. Sampson, Mark David Nellist, Phillip Brook-Carter, Magitha Maheshwar, Dirkje Jorijnte Johanna Halley, Lambertus Antonius Jacobus Janssen, Arjenne Lique Wilhelma Hesseling, Anna Maria Wilhelmina van den Ouweland, Peter Charles Harris, Christopher James Ward, Martin Hendrik Breuning, Jeroen Hendrik Roelfsema
-
Patent number: 6114109Abstract: A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.Type: GrantFiled: May 22, 1998Date of Patent: September 5, 2000Assignee: RiboTargets, Ltd.Inventors: Jonathan Karn, Michael J. Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 5770398Abstract: Vectors for the integration of a gene into the genetic material of a mammalian host cell such that the gene may be expressed by the host cell comprise a promoter and the gene and include a dominant activator sequence capable of eliciting host cell-type restricted, integration site independent, copy number dependent expression of the gene.Type: GrantFiled: June 7, 1995Date of Patent: June 23, 1998Assignee: Medical Research CouncilInventors: Franklin Grosveld, Dimitris Kioussis
-
Patent number: 5744456Abstract: Vectors for the integration of a gene into the genetic material of a mammalian host cell such that the gene may be expressed by the host cell comprise a promoter and the gene and include a dominant activator sequence capable of eliciting host cell-type restricted, integration site independent, copy number dependent expression of the gene.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Medical Research CouncilInventors: Franklin Grosveld, Dimitris Kioussis
-
Patent number: 5736359Abstract: Vectors for the integration of a gene into the genetic material of a mammalian host cell such that the gene may be expressed by the host cell comprise a promoter and the gene and include a dominant activator sequence capable of eliciting host cell-type restricted, integration site independent, copy number dependent expression of the gene.Type: GrantFiled: June 7, 1995Date of Patent: April 7, 1998Assignee: Medical Research CouncilInventors: Franklin Grosveld, Dimitris Kioussis